Le Lézard
Classified in: Health
Subject: PARTNERSHIPS

Appriss Health Partners with QS/1(R) to Integrate NarxCare into its Pharmacy Management Software


LOUISVILLE, KY--(Marketwired - May 11, 2017) - Appriss Health, provider of the most comprehensive platform for substance use disorder in the U.S., announced a partnership with QS/1 to integrate NarxCare into QS/1's Pharmacy Management Systems. NarxCare is an in-workflow, prescription drug monitoring program (PDMP), information, advanced analytics, tools and technology solution that aids clinical decision-making for patient safety and compliance to help physicians and pharmacists prevent and manage substance use disorder (SUD).

QS/1 provides the industry's premier pharmacy software for community, chain, and long-term care and outpatient pharmacies. Its network of 23 regional offices provides services, customer support, ongoing enhancements, product development and regulatory updates to help pharmacies become more successful.

NarxCare is a comprehensive platform to identify, prevent and manage SUD. It aggregates and analyzes prescription information from providers and pharmacies and presents visual, interactive information, as well as advanced analytic insights, complex risk scores and more to help physicians, pharmacists and care teams to provide better patient safety and outcomes.

Furthermore, NarxCare provides tools and resources that support patients' needs and connects them to treatment, if necessary. This information, insight and functionality is all accessed in-workflow through existing electronic health records (EHR) or pharmacy management systems, so there is no logging in or out of secondary websites or trying to manage user names or passwords.

"This partnership represents a powerful and unique opportunity to exchange potentially life-saving patient information that can alert pharmacists of possible overuse or abuse of prescription drugs," said Ed Vess, R.Ph., QS/1 senior manager of Market Analysts and president of the South Carolina Pharmacy Association. "We are very proud that, through this partnership with Appriss Health, pharmacists can now access PDMP data and NarxCare analytics directly from within QS/1's Pharmacy Management System workflow."

QS/1 is the first pharmacy management system to partner with Appriss Health to fully-integrate NarxCare into its workflow.

"We are very pleased to partner with QS/1 on this important and exciting initiative," said Rob Cohen, president of Appriss Health. "NarxCare will provide pharmacists, within their day-to-day activities, the critical tools and resources to help better support patients for earlier intervention in addressing substance use disorder. Dispensers will now have tried, true and immediate insight into a patient's prescription history along with the ability to communicate with healthcare providers and other pharmacists involved in the patient's care. We want to thank QS/1 and many others for taking the next step with us, including state and federal government agencies, hospitals and health systems across the U.S., in the battle against prescription drug addiction."

About QS/1
QS/1 offers industry-leading healthcare software solutions to effectively manage independent, chain, hospital outpatient and long-term care pharmacies and HME businesses. QS/1's complete software solutions are flexible and scalable, making them a valuable and affordable productivity tool for pharmacies - large or small. QS/1 is a division of the J M Smith Corporation, one of the largest privately-held companies in South Carolina. For additional information about QS/1 and the products and services it provides, visit www.qs1.com or call 800.231.7776.

About Appriss Health

Appriss Health provides the nation's most comprehensive platform for early identification, prevention and management of substance use disorder (SUD), within clinical workflow. We provide government agencies with a repository of controlled substance dispensing information combined with advanced analytics, and deliver real-time clinical decisioning support, critical insights and interventions to physicians, pharmacists, and care team members through millions of patient encounters each year. Our solutions enable the assessment and management of clinical risk in order to positively impact patient safety and population health outcomes. For more information, please visit www.apprisshealth.com.


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: